Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 19%
Buy 56%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie has demonstrated a strong financial outlook following management's upward revisions, notably projecting global sales in the Neuroscience segment to reach approximately $10.7 billion by 2025, an increase from earlier forecasts. The company also raised its FY 2025 EPS guidance to a range of $12.09-$12.29 and adjusted revenue estimates upward by $700 million to around $59.7 billion, reflecting robust commercial performance driven by key products such as Skyrizi and Rinvoq. Additionally, AbbVie's first-quarter 2025 sales of $13.34 billion exceeded both internal and consensus expectations, indicating solid growth across its immunology and oncology franchises, despite some challenges in aesthetics and Humira sales.

Bears say

AbbVie faces significant risks that contribute to a negative outlook, including disappointing commercial performance across key products such as Skyrizi, Rinvoq, and Botox, which are critically reliant on market execution. The upcoming competition from biosimilars for Humira in 2025 is expected to lead to greater market share erosion, while limited growth in the neuroscience segment and challenges in the aesthetics portfolio are exacerbated by ongoing macroeconomic pressures. Additionally, pipeline delays, potential regulatory hurdles, and competitive dynamics in the oncology sector further complicate AbbVie's ability to meet long-term growth expectations, presenting further headwinds for the company's financial stability.

AbbVie (ABBV) has been analyzed by 16 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 56% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 16 analysts, AbbVie (ABBV) has a Buy consensus rating as of Nov 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $241.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $241.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.